Skip to content

Danish Life Sciences Forum


The Danish Trade Council
Lundbeck Canada Inc. Novo Nordisk Canada Inc. LEO Pharma Inc. Canada


Formalized in March 2018, the Danish Life Sciences Forum is a group of three Danish pharmaceutical affiliates in Canada (Novo Nordisk Canada, Lundbeck Canada, and LEO Pharma) who all share a similar interest in the long-term sustainability of the innovative life sciences industry in Canada.

Danish Life Sciences Forum members are all foundation-based companies. These foundations have a mandate to develop social and economic benefits to all and not just the shareholders. A substantial portion of their revenue is redirected to support research and education as well as contribute to civil society, culture, and the economy.

The Forum is committed to engaging with public and private sector stakeholders in Canada to help ensure that the life sciences industry continues to be an important source of jobs, economic growth, and improved health outcomes for Canadians.

Opportunities and Challenges

Denmark and Canada not only share a physical 4,000 km border, but they also have many other similarities, including standard of living, business culture, societal values, as well as a general ambition to be ahead of the curve when it comes to finding innovative solutions to problems.

We believe that given our similarities, we have a lot that we can learn from each other, including our approaches to creating a business-friendly environment and regulatory framework that allows for innovation, better access, and growth in the life sciences sector.

News and Events

Treasury Board Secretariat’s regulatory modernization initiative submission – September 14, 2018

The Danish Life Sciences Forum provided input on the Treasury Board Secretariat’s regulatory modernization initiative. The submission is complementary to that of the industry association, Innovative Medicines Canada (IMC), and focuses on one of the three key sectors that have been targeted for the three-year regulatory review process: health and bio-sciences. The submission focuses on Health Canada’s proposed reform of the PMPRB, which runs contrary to the Treasury Board Secretariat’s efforts to streamline regulation in health and bio-sciences. Please review the full submission here.

Growing the Lifesciences Industry: Improving Access, Affordability & Appropriate Use of Medicines - Can we have it all?

Together with the Economic Club of Canada, we will be bringing stakeholders from both Canada and Europe to dialogue about important issues related to access and affordability of innovative medicines, and growing a strong, innovative lifesciences industry that creates jobs and stimulates economic growth and international trade. The panel discussion will be moderated by Ilse Treurnicht, Former CEO, MaRS Discovery District, and panellists will include Brian Hilberdink, CEO, Novo Nordisk Canada Inc., and Hans Erik Henriksen, CEO, Healthcare Denmark. This event will be taking place at the Chateau Laurier in Ottawa on September 25, 2018.

Please visit the Event Website today, and purchase your ticket here:

Pre-Budget Submission

In response to the Pre-Budget Consultations in advance of the 2019 budget launched by the Standing Committee on Finance, the Danish Life Sciences Forum submitted recommendations to support the topic of Economic Growth: Ensuring Canada's Competitiveness. The Danish Life Sciences Forum has offered its perspectives on how the federal government can use innovation in the life sciences industry as a way to diversify the economy, increase productivity and competitiveness, and attract and retain the jobs of tomorrow. Please review the full pre-budget submission here.

Denmark Launches a Life Sciences Growth Plan

Denmark has launched a new growth plan for life sciences, which aims to strengthen one of Denmark's leading industries. The plan includes 36 initiatives, targeting barriers and opportunities for the industry across the entire value chain. Although Danish life sciences companies are already leading in global markets, there is general recognition that in order to remain competitive, it requires a constant focus on strengthening innovation, research and product development.





contact uS:

Kerry Allerton

Senior Trade Advisor
Healthcare and Life Sciences
001 (416) 640 1301